caris-life-sciences-announces-appointment-of-lloyd-b.-minor-to-board-of-directors

Caris Life Sciences Announces Appointment of Lloyd B. Minor to Board of Directors

 

Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today the appointment of Lloyd B. Minor, M.D. to the Caris Board of Directors, effective immediately. Following the appointment of Dr. Minor, the Board will be comprised of 11 directors.

The Caris Life Sciences Board is composed of a diverse group of leaders with distinct perspectives. Many of the current directors have held leadership roles at major domestic and international companies, academic and scientific organizations, and governmental agencies.

“We are excited to welcome Dr. Minor to the Caris Board,” said David D. Halbert, Chairman and CEO of Caris Life Sciences. “Dr. Minor’s combined expertise in academia and science has established him as a leading advocate for innovation in the field of precision healthcare and his perspectives will be invaluable as we reinvent the way medicine is practiced, and pursue our vision to improve patient outcomes across all disease types worldwide.”

“I am pleased to join the Caris Board, and welcome the opportunity to contribute to Caris’ future growth and success as the company advances innovative technologies,” said Dr. Minor. “I look forward to working alongside fellow board members, and Caris’ management team, to collectively revolutionize patient care.”

Lloyd B. Minor, M.D., is a scientist, surgeon and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since December 2012. As dean, Dr. Minor plays an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Children’s Health and Lucile Packard Children’s Hospital Stanford. He also oversees the quality of Stanford Medicine’s physician practices and growing clinical networks. An advocate for innovation, Dr. Minor has provided significant support for fundamental science and for clinical and translational research at Stanford. Through bold initiatives in medical education and increased support for Ph.D. students, Dr. Minor is committed to inspiring and training future leaders. Before coming to Stanford, Dr. Minor was provost and senior vice president for academic affairs of The Johns Hopkins University. During his time as provost, Dr. Minor launched many university-wide initiatives such as the Gateway Sciences Initiative to support pedagogical innovation, and the Doctor of Philosophy Board to promote excellence in Ph.D. education. He worked with others around the university and health system to coordinate the Individualized Health Initiative, which aimed to use genetic information to transform health care. In 2012, Dr. Minor was elected to the National Academy of Medicine, formerly the Institute of Medicine.

caris-life-sciences-announces-appointment-of-mike-weinstein,-medical-technology-executive-and-wall-street-veteran,-as-chief-financial-officer

Caris Life Sciences Announces Appointment of Mike Weinstein, Medical Technology Executive and Wall Street Veteran, as Chief Financial Officer

 

Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, announced today the appointment of Mike Weinstein as Executive Vice President and Chief Financial Officer.

“We are thrilled to welcome Mike to the Caris team,” said David D. Halbert, Chairman and CEO of Caris Life Sciences. “His passion for our mission, industry experience and strategic thinking will provide strong leadership as we position Caris for the next phase; expanding our offering to include both tissue and blood (measuring all coding genes) across hereditary and acquired variants, resulting in the most comprehensive offering ever.”

“I am delighted to join Caris at such an exciting time,” said Weinstein. “In my 25-plus years, I’ve seen few companies with Caris’ potential to grow and to change the way we diagnose, monitor, treat and care for hundreds of thousands of cancer patients each year.”

In May, Caris announced an $830 million growth equity round at a $7.83 billion post-money valuation. The round was led by Sixth Street, a leading global investment firm making its third investment in Caris since 2018. Funds and accounts advised by T. Rowe Price Associates, Inc., Silver Lake, Fidelity Management & Research Company LLC, and Coatue were significant participants in the round. Additional investors included Columbia Threadneedle Investments, Canada Pension Plan Investment Board, Millennium Management, Neuberger Berman Funds, Highland Capital Management, Rock Springs Capital, OrbiMed, ClearBridge Investments, Tudor Investment Corporation, Eaton Vance Equity (Morgan Stanley), Pura Vida Investments and First Light Asset Management.

Mr. Weinstein brings to Caris more than 25 years of finance and life sciences experience.  Prior to joining the Company, Weinstein served as Senior Vice President, Strategy at Medtronic and was a member of the Executive Committee. In that role he oversaw global strategy for the organization, including providing counsel and input on business development, capital deployment, and the overall strategic direction of each of Medtronic’s businesses. Prior to Medtronic, Weinstein was a Managing Director at JPMorgan Chase & Co., leading the firm’s healthcare group within equity research. Weinstein is a 14-time #1 ranked analyst in the annual surveys of both Institutional Investor and Greenwich Associates. In 2013, he was named to the Institutional Investor Hall of Fame. He is a summa cum laude graduate of Georgetown University and serves on the Board of Advisors for Georgetown’s McDonough School of Business.